Output details

Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial

PARSPORT represents the first phase III multi-centre randomised controlled trial to demonstrate that using IMRT to spare the parotid glands significantly reduces the incidence of xerostomia (dry mouth syndrome) in squamous cell carcinoma of the head and neck. It contributed to IMRT becoming the worldwide standard of care. Chris Nutting acted as Chief Investigator and contributed to patient recruitment; Emma Hall (Clinical Trials and Statistics Unit) was Chief Statistician. Both collaborated on trial design and management, data interpretation and writing the paper. This influential work demonstrates the ICR’s multidisciplinary team approach to research.